Table 1.
Characteristics of the included studies in the systematic review
| Author, year | Country | Type of study | Study subject | Sample size | Dose of supplementation | Intervention group | Control group | Mean age or age range(Y) | Outcome | Intervention duration | Measurement interval | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Asemi, 2015 | Iran | RCT | GDM Women |
I = 35 C = 35 |
200 µg/d | MT | placebo | 28.6 ± 4.6 | hs-CRP (ng/mL)NO (mmol/L) | 6 weeks from weeks 24 to 28 of gestation | Baseline and end of study |
| 2 | Shargorodsky, 2010 | Israel | RCT | Patient with > 2 CVD RFs |
I = 36 C = 34 |
100 µg/d | CT | placebo | 62.17 ± 6.21 |
hs-CRP(mg/dl) Homocysteine(μmol/l) Ur cathacholamines(mg/24 h) |
6 months | Base line and end of study |
| 3 | Ravn-Haren, 2007 | Denmark | R cross over |
Diabetic Men |
I = 20 C = 20 |
300 µg/d | CT | placebo | 26·8 | CRP | 1 week | Baseline and after 1 week and end of study |
| 4 | Alizadeh, 2012 | Iran | RCT | Premenopausal women with central obesity |
I = 17 C = 17 |
200 µg/d | CT | placebo | 33.9 ± 8.5 | hs-CRP, mg/l NOx, _mol/l |
2 weeks run-in period 6 weeks intervention period |
Baseline and after 3, and 6 weeks |
| 5 | Murer, 2014 | Switzerland | RCT | Obese children and adolescents |
I = 23 C = 21 |
50 µg/d | CT | placebo | 12.7 ± 1.5 | CRP,2 mg/L serum | 4 months | Baseline and after 4 months |
| 6 | Razavi, 2016 | Iran | RCT | PCOS patients |
I = 32 C = 32 |
200 µg/d | MT | placebo | 18–40 |
hs-CRP (ng/ml) NO (μmol/l) |
8 weeks | Baseline and after 2 months |
| 7 | Farrokhian, 2016 | Iran | RCT | Patients with type 2 diabetes & CVD | I = 30 C = 30 | 200 µg/d | MT | placebo | 40–85 | hs-CRP (ng/ml) NO (μmol/l) | 8 weeks | Baseline and after 2 months |